Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Vireo Growth's Sloan Ratio for the quarter that ended in Mar. 2026 was -12.79%.
As of Mar. 2026, Vireo Growth has a Sloan Ratio of -12.79%, indicating there is a warning stage of accrual build up.
Vireo Growth (OTCPK:VREOF) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, Vireo Growth has a Sloan Ratio of -12.79%, indicating there is a warning stage of accrual build up.
Vireo Growth Sloan Ratio % Related Terms
Vireo Growth Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Vireo Growth's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth Sloan Ratio % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Vireo Growth's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Vireo Growth's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Vireo Growth's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was -14.934 (Jun. 2025 ) + -26.299 (Sep. 2025 ) + -20.372 (Dec. 2025 ) + -20.3 (Mar. 2026 ) = $-81.9 Mil.
Vireo Growth's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was -4.751 (Jun. 2025 ) + -6.793 (Sep. 2025 ) + 18.656 (Dec. 2025 ) + 11.9 (Mar. 2026 ) = $19.0 Mil.
Vireo Growth's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was 34.038 (Jun. 2025 ) + -14.757 (Sep. 2025 ) + -9.422 (Dec. 2025 ) + 8 (Mar. 2026 ) = $17.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth (VREOF) has a Sloan Ratio % of -12.79% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Vireo Growth and its competitors.
Is Vireo Growth's Sloan Ratio % too high?
Vireo Growth's current Sloan Ratio % is -12.79%. Overall, Vireo Growth has a GF Score™ of 44/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's Sloan Ratio % compare to ZTS and UTHR?
Vireo Growth's Sloan Ratio % of -12.79% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Drug Manufacturers company?
A good Sloan Ratio % depends on the Drug Manufacturers industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Vireo Growth and its competitors. Vireo Growth's current Sloan Ratio % is -12.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (VREOF) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.63, compared to a current price of $9.78 — trading 28.2% above its estimated fair value. The current Sloan Ratio % is -12.79%. Vireo Growth's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Vireo Growth (VREOF), the current Sloan Ratio % is -12.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (VREOF) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued.
The current stock price of $9.78 is trading 28.2% above its estimated GF Value™ of $7.63.
GuruFocus considers Vireo Growth to be Modestly Overvalued.
Key valuation signals for VREOF:
Sloan Ratio %: -12.79%
GF Value™: $7.63 vs. price of $9.78 (28.2% above fair value)
No single metric tells the full story. See the VREOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
44GF Score
Get the complete analysis for VREOF
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VREOF has been successfully added to your 
